Table 1

Characteristics of the study subjectsa

Variable

SpA group

(n = 122)

AS group

(n = 95)

nrSpA group

(n = 27)

Control group

(n = 75)


Male:female ratio (% male)

90:32 (73.8)

73:22 (76.8)

17:10 (63.0)

42:33 (56.0)

Age, years

33.8 [17.3 to 71.6]

35.7 [17.3 to 71.6]

27.0 [18.8 to 44.8]

30.3 [17.7 to 63.8]

Symptom duration, years

7.0 [0.3 to 41.0]

11.0 [0.3 to 41.0]

1.2 [0.3 to 5.0]

N/A

HLA-B27-positive, n (%)b

105/120 (87.5)

81/93 (87.1)

24/27 (88.9)

N/A

BASDAI, NRS range 0 to 10

4.4 [0.4 to 9.0]

4.6 [0.4 to 9.0]

3.9 [0.8 to 6.3]

N/A

BASFI, NRS range 0 to 10

2.9 [0 to 8.2]

3.2 [0 to 7.8]

2.1 [0 to 8.2]

N/A

BASMI, NRS range 0 to 10

1.0 [0 to 8.0]

1.0 [0 to 8.0]

0 [0 to 4.0]

N/A

CRP level, mg/L

5.0 [0 to 150.0]

5.0 [0 to 57.0]

3.0 [0 to 150.0]

N/A

ESR (mm/hour)

12.5 [1.0 to 72.0]

14.0 [2.0 to 69.0]

8.5 [1.0 to 72.0]

N/A


aAS = ankylosing spondylitis; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index [23]; BASFI = Bath Ankylosing Spondylitis Functional Index [24]; BASMI = Bath Ankylosing Spondylitis Metrology Index [25]; CRP = C-reactive protein, reference range ≤5 mg/L; ESR = erythrocyte sedimentation rate; HLA-B27 = human leukocyte antigen B27; N/A = not applicable; NRS = numeric rating scale; nrSpA = nonradiographic axial spondyloarthritis; SpA = spondyloarthritis. bHLA-B27 was not tested in two patients in the AS group. Values for the continuous demographic and clinical variables are medians [IQR] unless otherwise stated.

Weber et al. Arthritis Research & Therapy 2012 14:R3   doi:10.1186/ar3551

Open Data